From: Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
Patient no | Gender | Cycle no | Adverse event | Time to symptoms | Death | Causality scoresa | Conclusion | |||
---|---|---|---|---|---|---|---|---|---|---|
1 | F | 1 | Intracerebral hemorrhage | 5 days | 5 days | 1 | 1 | 1 | 2 | Probable |
2 | F | 1 | Listeria encephalitis | 10 days | 12 days | 1 | 1 | 1 | 1 | Probable |
3 | F | 1 | Septic shock, multiple organ failure | 3 days | 15 days | 2 | 1 | 2 | 2 | Probable |
4 | F | 1 | Septic shock, multiple organ failure | 14 days | 16 days | 1 | 1 | 2 | 2 | Probable |
5 | F | 1 | Pneumonia | 16 days | 22 days | 2 | 1 | 2 | 2 | Probable |
6 | F | 1 | Neutropenia, Staphylococcus aureus infection, septic shock | 27 days | 28 days | 1 | 1 | 1 | 2 | Probable |
7 | F | 1 | Autoimmune hemolytic anemia, septic shock, DIC | 8 months | 8 months | 1 | 1 | 1 | 1 | Probable |
8 | M | 2 | Immune-mediated thrombocytopenia, brain stem hemorrhage | 5 months | 9 months | 2 | 1 | 1 | 1 | Probable |
9 | F | NR | Autoimmune hepatitis | 15 months | 16 months | 2 | 2 | 1 | 2 | Probable |
10 | F | 2 | Agranulocytosis, Clostridium colitis, Aspergillus pneumonia | 17 months | 18 months | 2 | 1 | 3 | 3 | Possible |